Search

Certara Inc

Avatud

SektorTervishoid

6.81 -2.44

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.77

Max

6.99

Põhinäitajad

By Trading Economics

Sissetulek

-2.9M

-8.8M

Müük

3.3M

107M

P/E

Sektori keskmine

100.714

60.149

Aktsiakasum

-0.06

Kasumimarginaal

-8.196

Töötajad

1,515

EBITDA

-16M

16M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+12.41% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

4. aug 2026

Turustatistika

By TradingEconomics

Turukapital

258M

1.1B

Eelmine avamishind

9.25

Eelmine sulgemishind

6.81

Uudiste sentiment

By Acuity

19%

81%

32 / 340 Pingereas Healthcare

Certara Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. juuli 2026, 19:31 UTC

News

Certara Inc partners with NVIDIA to enhance its AI biosimulation platform. Shares are higher, reflecting positive market sentiment around the collaboration.

Võrdlus sarnastega

Hinnamuutus

Certara Inc Prognoos

Hinnasiht

By TipRanks

12.41% tõus

12 kuu keskmine prognoos

Keskmine 7.79 USD  12.41%

Kõrge 10 USD

Madal 6 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Certara Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

3

Osta

6

Hoia

0

Müü

Sentiment

By Acuity

32 / 340 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat